Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, BTIG Research restated a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tvardi Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.50.

Tvardi Therapeutics Price Performance

Shares of Tvardi Therapeutics stock opened at $3.02 on Friday. The company has a 50 day simple moving average of $3.71 and a two-hundred day simple moving average of $8.70. The firm has a market cap of $28.33 million, a PE ratio of -0.54 and a beta of 0.16. Tvardi Therapeutics has a 1 year low of $2.81 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Slate Path Capital LP purchased a new stake in Tvardi Therapeutics in the second quarter worth about $16,427,000. American Financial Group Inc. purchased a new position in shares of Tvardi Therapeutics during the 4th quarter worth approximately $962,000. 683 Capital Management LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $4,107,000. Vestal Point Capital LP bought a new position in shares of Tvardi Therapeutics in the 3rd quarter worth approximately $6,508,000. Finally, Geode Capital Management LLC bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $2,617,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.